Drugs Made In America Acquisition Corp. (DMAAU) Stock Price & Analysis
Drugs Made In America Acquisition Corp. (DMAAU) closed at USD 10.79 on Wednesday, October 14, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.79; the Oct 14, 2026 session ranged USD 10.79–10.79 on volume of 0 shares. Market capitalization is —, with a 52-week range of USD 10.3–12.5 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DMAAU.md
Key facts (DMAAU)
- Analysts: None.
- Total return with dividends: 1Y +4.7% vs S&P 500 +18.1%; 5Y +7.7% vs S&P 500 +85.1%.
Analysts (DMAAU)
Consensus None.
Total return (dividends reinvested) (DMAAU)
| 1Y (from 2025-10-16) | 5Y (from 2025-01-27) | |
|---|---|---|
| Total return | +4.7% | +7.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +4.7% | +4.5% |
| Volatility (annualized) | 12.6% | 10.1% |
| Max drawdown | -9.3% (Jun 2026→Jun 2026) | -9.3% (Jun 2026→Jun 2026) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 10.79 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 10.79 |
| Open | USD 0 |
| Day Range | USD 10.79 – 10.79 |
| 52-Week Range | USD 10.3 – 12.5 |
| Volume | 0 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (DMAAU)
Nexqual's technical model rates DMAAU "BUY" based on 5 bullish and 1 bearish signals across 126 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 10.87) |
| MACD | 0.04 (positive) |
Analyst Ratings (DMAAU)
Wall Street analysts rate DMAAU "None", per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|
Earnings (DMAAU)
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (DMAAU)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.02 |
| Total Cash | $20,280 |
| Total Debt | $350,000 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (DMAAU)
Nexqual rates Drugs Made In America Acquisition Corp.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $20K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$517K (TTM) |
| Efficiency | Mixed — No data |
Ownership (DMAAU)
| Insider Ownership | +17.88% |
|---|---|
| Institutional Ownership | +1.54% |
| Shares Outstanding | 29.17M |
| Float | 19.79M |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (DMAAU)
Drugs Made In America Acquisition Corp. is led by Roger Bendelac (age 68), Chief Executive Officer, per Nexqual as of October 16, 2026 at 05:11 UTC.
| Chief Executive Officer | Roger Bendelac (age 68) |
|---|---|
| CFO & Principal Accounting Officer | Saleem Elmasri (age 38) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VYLR | Vylor Inc. | USD 73.34 | ▼ 4.68% |
| DMII | Drugs Made In America Acquisiti | USD 10.19 | ▲ 0% |
| CCXI | Churchill Capital Corp XI | USD 11.35 | ▲ 1.7% |
| EVAC | EQV Ventures Acquisition Corp. | USD 10.3 | ▼ 0.1% |
| BCSS | Bain Capital GSS Investment Cor | USD 10.22 | ▼ 0.15% |
| CEPF | Cantor Equity Partners IV, Inc. | USD 10.26 | ▼ 0.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt